Clinical bottom line
Paroxysmal nocturnal hemoglobinuria (PNH) refractory to standard complement C5 inhibitors remains a significant clinical challenge. Emerging therapeutic strategies targeting alternative complement pathways, inflammatory mediators, and novel molecular targets show promise in addressing breakthrough hemolysis and improving patient outcomes. These approaches warrant cautious consideration and further validation in refractory PNH populations.
What the evidence shows
PNH is a clonal hematopoietic stem cell disorder characterized by complement-mediated intravascular hemolysis due to deficiency of glycosylphosphatidylinositol (GPI)-anchored complement regulatory proteins (Kinoshita et al., 2003). The introduction of anti-C5 monoclonal antibodies revolutionized PNH management by reducing hemolysis and thrombosis risk. However, a subset of patients exhibit refractory disease manifesting as breakthrough hemolysis or incomplete response (Risitano et al., 2017).
Recent advances focus on complement inhibition beyond C5 blockade. Targeting proximal components such as C3 or factor D offers broader complement pathway suppression, potentially mitigating extravascular hemolysis and residual anemia seen with C5 inhibitors (Risitano et al., 2017). Additionally, novel agents modulating the alternative pathway or lectin pathway are under investigation, aiming to overcome resistance mechanisms.
Inflammation plays a contributory role in PNH pathophysiology. Elevated interleukin-6 (IL-6) levels have been implicated in hemolytic exacerbations and systemic symptoms (Zhao et al., 2026). Therapeutic targeting of IL-6 or its receptor may provide adjunctive benefit by dampening inflammatory cascades that exacerbate hemolysis and thrombosis risk.
Molecular insights into PNH pathogenesis have identified potential targets beyond complement, including modulation of clonal hematopoiesis and bone marrow microenvironment (Apostolidou et al., 2025). These avenues remain largely experimental but could inform future combination strategies.
Caveats and uncertainty
Current evidence for novel therapies in refractory PNH is largely derived from early-phase trials, preclinical studies, and mechanistic investigations (Risitano et al., 2017; Apostolidou et al., 2025). Robust randomized controlled trials are limited, and long-term safety data are lacking. The heterogeneity of refractory PNH phenotypes complicates patient selection and response assessment.
Inflammatory targeting, such as IL-6 blockade, remains hypothesis-generating with no definitive clinical trial evidence in PNH to date (Zhao et al., 2026). Potential immunosuppressive risks and effects on infection susceptibility require careful evaluation.
The interplay between complement inhibition and clonal hematopoiesis modulation is complex and incompletely understood. Translating molecular findings into effective therapies will require extensive validation.
How this may change practice
For hematologists managing refractory PNH, awareness of emerging complement inhibitors targeting proximal components may expand therapeutic options beyond C5 blockade. These agents could address residual hemolysis and anemia, improving quality of life.
Incorporating inflammatory biomarker assessment, such as IL-6 levels, might refine patient stratification and identify candidates for adjunctive anti-inflammatory therapies once validated.
Multidisciplinary collaboration and enrollment in clinical trials investigating novel agents are essential to advance care for refractory PNH patients. Personalized approaches integrating complement pathway profiling and molecular characterization may become feasible as evidence evolves.